ASTHMA
Conditions
Keywords
ASTHMA, TRIMBOW, TRIPLE THERAPY, BECLOMETHASONE, FORMOTEROL, GLYCOPYRRONIUM, TRIMAXIMIZE, REAL-WORLD SETTING, EXTRAFINE, SINGLE-INHALER, COHORT, PROSPECTIVE
Brief summary
TriMaximize, a non-interventional trial aims to collect prospective, longitudinal data from asthma patients under routine care, for whom their treating physician has decided to prescribe Trimbow® (beclometasone/formoterol/glycopyrronium).
Detailed description
TriMaximize, a non-interventional trial aims to collect prospective, longitudinal data from asthma patients under routine care, for whom their treating physician has decided to prescribe Trimbow® (beclometasone/formoterol/glycopyrronium). Trimbow is a fixed triple therapy containing a long-acting muscarinic antagonist (LAMA, glycopyrronium), a long-acting beta-adrenergic agonist (LABA, formoterol) and an inhaled corticosteroid (ICS, beclometasone). Asthma patients often need to use multiple inhalers as part of their therapy, which require different inhalation techniques. It has been shown that the use of several inhalers of different mode of action, design and dosage requirements may have a detrimental effect on patient adherence and subsequent treatment outcomes. In this prospective, non-interventional trial, the investigators aim to evaluate aspects of adherence to Trimbow, a single-inhaler triple therapy (SITT) as a maintenance treatment of asthma, to gather knowledge from routine care on whether appropriate step-up to SITT leads to greater adherence and better health outcomes.
Interventions
OTHERNon-interventional
As this is a non-interventional trial, only data obtained within the current routine management of asthma at outpatient respiratory centres or GP centres will be documented.
Sponsors
Gesellschaft für Therapieforschung mbH
Chiesi SAS
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients ≥ 18 years of age, * Patients with confirmed leading diagnosis of asthma with or without concomitant COPD, * Physician decision to start fixed triple therapy with ICS/LABA/LAMA (Trimbow® MS or HS) according to its current authorised indication. The treatment decision must be made independently from participation in this NIS, * Patients willing and able to sign an informed consent for use of their pseudonymised clinical data within the present non-interventional study, * Patient must be covered by a social security scheme, * Patient must be treated by one of the practitioners of the centre (at office or at hospital).
Exclusion criteria
* Participation in an interventional clinical trial within 30 days prior to enrolment into the present non-interventional study or planned enrolment in an interventional clinical trial during the observational period. * Patients unable to understand scope of study or patients unwilling to participate in study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To describe patient characteristics and therapy pathways for patients with a diagnosis of moderate to severe asthma who are treated with Trimbow in real world practice | 12 months | Descriptive analysis of patient demographics. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Assess quality of life | 12 months | Change from baseline in Mini-AQLQ scores. |
| Assess treatment adherence | 12 months | Change from baseline in TAI scores. |
| Analyse parameters of lung function using spirometry | 12 months | Change from baseline in FEV1. |
| Analyse parameters of small airways disease | 12 months | Change from baseline in small airway function measured by pre-dose AUCAX (Area under the curve of reactance) using available oscillometry system. |
| Analyse parameters of asthma-related airway inflammation | 12 months | Change from baseline in percentage of patients with a fraction of exhaled nitric oxide (FeNO) below or above 20 ppb. |
| Analyse parameters of persistent airflow limitation | 12 months | Change from baseline in percentage of patients with persistent airflow limitation (PAL); PAL defined as post-BD FEV1 \<80% predicted and post-BD FEV1/FVC Ratio \< 0.7. |
| Assess asthma control (ACT) | 12 months | Change from baseline in ACT scores. |
| Analyse the severity of asthma exacerbations as defined by the American Thoracic Society/European Respiratory Society (ATS/ERS) classification of asthma exacerbations | 12 months | Severity of exacerbations, defined according to the ATS/ERS classification of asthma exacerbations, will be analysed 12 months prior to baseline and during study. |
| Analyse use of rescue medication | 12 months | Use of any rescue medication 7 days prior to baseline and during study 7 days prior to respective visit. |
| Analyse use of systemic corticosteroids | 12 months | Use of any systemic corticosteroids 12 months prior to baseline and during study. |
| Assess adverse events associated with use of Trimbow | 12 months | Assessment of the number and type of adverse events. |
| Assess retention rate with Trimbow | 12 months | Assess continuation of treatment with Trimbow (retention rate of Trimbow) at month 12. |
| Analyse the incidence of asthma exacerbations | 12 months | Number of exacerbations 12 months prior to baseline and during study. |
Countries
France
Contacts
Primary ContactChristine CONTRE, Dr
Backup ContactJustine FIOCCA, Pharm.D
Outcome results
None listed